Table 1.
Baseline patient and disease characteristics by patient status and country
| Outpatients | Inpatients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Argentina | Hungary | Mexico | Peru | Poland | Total | Argentina | Hungary | Mexico | Peru | Poland | Total | |
| N = 75 | N = 75 | N = 75 | N = 101 | N = 75 | N = 401 | N = 75 | N = 81 | N = 77 | N = 78 | N = 75 | N = 386 | |
| Gender, male, n (%) | 40 (53.3) | 33 (44.0) | 31 (41.3) | 58 (57.4) | 41 (54.7) | 203 (50.6) | 46 (61.3) | 45 (55.6) | 39 (50.6) | 43 (55.1) | 46 (61.3) | 219 (56.7) |
| Age, years, mean (SD) | 3.8 (2.4) | 4.4 (2.0) | 3.0 (3.2) | 3.3 (3.3) | 3.9 (2.6) | 3.6 (2.8) | 2.9 (2.2) | 3.7 (2.1) | 2.6 (3.5) | 2.4 (3.4) | 4.2 (2.3) | 3.1 (2.8) |
| Race, n (%) | ||||||||||||
| Caucasian | 4 (5.3) | 75 (100) | 2 (2.7) | – | 75 (100) | 156 (38.9) | 7 (9.3) | 81 (100) | 3 (3.9) | 2 (2.6) | 75 (100) | 168 (43.5) |
| Hispanic/Latino | 71 (94.7) | – | 61 (81.3) | 90 (89.1) | – | 222 (55.4) | 68 (90.7) | – | 69 (89.6) | 46 (59.0) | – | 183 (47.4) |
| Latino/Mestizo/Indigenous | – | – | 12 (16.0) | 11 (10.9) | – | 23 (5.7) | – | – | 5 (6.5) | 30 (38.5) | – | 35 (9.1) |
| Area of residence, n (%) | ||||||||||||
| Rural | 4 (5.3) | 4 (5.3) | 13 (17.3) | 4 (4.0) | 7 (9.3) | 32 (8.0) | 12 (16.0) | 28 (34.6) | 16 (20.8) | 23 (29.5) | 23 (30.7) | 102 (26.4) |
| Urban | 70 (93.3) | 71 (94.7) | 62 (82.7) | 97 (96.0) | 64 (85.3) | 364 (90.8) | 62 (82.7) | 53 (65.4) | 61 (79.2) | 55 (70.5) | 51 (68.0) | 282 (73.1) |
| Not available | 1 (1.3) | – | – | – | 4 (5.3) | 5 (1.2) | 1 (1.3) | – | – | – | 1 (1.3) | 2 (0.5) |
| Maximum number of skin lesions, n (%) | ||||||||||||
| < 50 | 20 (26.7) | 51 (68.0) | 27 (36.0) | 56 (55.4) | 25 (33.3) | 179 (44.6) | 3 (4.0) | 2 (2.5) | 20 (26.0) | 1 (1.3) | 18 (24.0) | 44 (11.4) |
| 50–249 | 36 (48.0) | 16 (21.3) | 44 (58.7) | 35 (34.7) | 36 (48.0) | 167 (41.6) | 50 (66.7) | 59 (72.8) | 45 (58.4) | 7 (9.0) | 37 (49.3) | 198 (51.3) |
| 250–500 | 17 (22.7) | 7 (9.3) | 4 (5.3) | 9 (8.9) | 14 (18.7) | 51 (12.7) | 14 (18.7) | 20 (24.7) | 11 (14.3) | 50 (64.1) | 12 (16.0) | 107 (27.7) |
| > 500 | 2 (2.7) | 1 (1.3) | – | 1 (1.0) | – | 4 (1.0) | 8 (10.7) | – | 1 (1.3) | 20 (25.6) | 8 (10.7) | 37 (9.6) |
| Immuno-compromised, yes, n (%)a | 1 (1.3) | – | 1 (1.3) | – | – | 2 (0.5) | 1 (1.3) | 4 (4.9) | 5 (6.5) | 1 (1.3) | – | 11 (2.8) |
SD Standard Deviation
aPatients were considered immunocompromised if they had ≥1 of the following conditions: HIV/AIDS, congenital immunodeficiency, received systemic steroids, or had any other immunocompromised condition listed in their medical history